Market research
RHT.AU Resonance Health Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.15
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU000000RHT2
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.15
About
About Resonance Health Limited
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms comprising FerriScan, R2*/T2*, T1CMR, and T2CMR phantoms for the calibration of MRI machines. In addition, the company operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors. It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RHT.AU discussion.
5 years, 5 months ago
Resonance Health Limited is currently in a long term downtrend where the price is trading 3.4% below its 200 day moving average.
From a valuation standpoint, the stock is 90.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.6.
Resonance Health Limited's total revenue rose by 9.5% to $2M since the same quarter in the previous year.
Its net income has increased by 168.6% to $770K since the same quarter in the previous year.
Finally, its free cash flow grew by 413.5% to $531K since the same quarter in the previous year.
Based on the above factors, Resonance Health Limited gets an overall score of 4/5.